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Response to targeted therapies varies signiﬁcantly despite shared oncogenic mutations. Nowhere is this more
apparent than in BRAF (V600E)-mutated melanomas where initial drug response can be striking and yet relapse is
commonplace. Resistance to BRAF inhibitors have been attributed to the activation of various receptor tyrosine
kinases (RTKs), although the underlying mechanisms have been largely uncharacterized. Here, we found that
EGFR-induced vemurafenib resistance is ligand dependent. We employed whole-genome expression analysis
and discovered that vemurafenib resistance correlated with the loss of microphthalmia-associated transcription
factor (MITF), along with its melanocyte lineage program, and with the activation of EGFR signaling. An inverse
relationship between MITF, vemurafenib resistance, and EGFR was then observed in patient samples of recurrent
melanoma and was conserved across melanoma cell lines and patients’ tumor specimens. Functional studies
revealed that MITF depletion activated EGFR signaling and consequently recapitulated the resistance phenotype.
In contrast, forced expression of MITF in melanoma and colon cancer cells inhibited EGFR and conferred
sensitivity to BRAF/MEK inhibitors. These ﬁndings indicate that an “autocrine drug resistance loop” is suppressed
by melanocyte lineage signal(s), such as MITF. This resistance loop modulates drug response and could explain
the unique sensitivity of melanomas to BRAF inhibition.
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INTRODUCTION
Primary and secondary resistance to molecular therapies
remains a cardinal challenge in the clinical setting. For
metastatic melanoma, the pace of progress from the benchside
discovery of BRAF (V600E) to the bedside delivery of
vemurafenib (VEM) has been rapid. As with other targeted
agents, however, acquired resistance to selective BRAF
inhibitors (SBIs) soon followed on the heels of clinical success.
COT expression (Johannessen et al., 2010), SOX10 reduction
(Sun et al., 2014), BRAF ampliﬁcation (Shi et al., 2012), splice
variation (Poulikakos et al., 2011), NRAS mutagenesis, and
receptor tyrosine kinase (RTK) activation (Nazarian et al., 2010;
Villanueva et al., 2010; Yadav et al., 2012; Girotti et al., 2013)
have all been linked to SBI resistance in melanoma. Although
these mechanisms all confer a similar phenotype of mediating
cell survival and proliferation, the relative contribution of
subclonal selection versus epigenetic reprogramming of cell
state to the emergence of each mechanism is not known. On
the other hand, the lineage dependency of SBI sensitivity
suggests that cellular differentiation state might underlie any of
the previously described mechanisms of resistance to SBIs.
We thus set out to characterize changes in transcriptional
programming that occur during the course of in vitro selection
for VEM resistance. Using a forward pharmacogenetic screen,
we discovered that VEM resistance was associated with
different degrees of cellular reprogramming. On one hand,
resistance that emerges from a BRAF splice product is
associated with minimal changes in cell state. On the other
hand, resistance can also be associated with signiﬁcant
transcriptome changes anchored by the concomitant loss of
the master melanocyte lineage regulator, microphthalmia-
associated transcription factor (MITF), with the activation of
EGFR, a pathway little utilized in these neural crest–derived
cells. We show that modulating MITF levels alters VEM
sensitivity in both melanoma and colon cancer, and that a
reciprocal relationship between MITF and EGFR is conserved
across melanoma specimens and correlates with VEM
response. Our studies point to lineage identity as a major
determining factor for SBI sensitivity.
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RESULTS
In order to elucidate programmatic changes that occur with
VEM resistance, we subjected two melanoma cell lines, A375
and SKmel-28, to escalating doses of VEM in order to generate
isogenically matched pairs of sensitive and resistant cell lines.
Dose interrogation showed that both resistant cell lines (i.e.,
A375R and SKmel-28R exhibited 410-fold increase in
their VEM 50% growth inhibition GI50s; Figure 1a) compared
with their parental counterparts. Both resistant lines
showed increased pAKT473 and reengagement of mitogen-
activated protein kinase signaling, although the A375R cells
retained sensitivity to MEK (mitogen-activated protein kinase/
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Figure 1. Characteristics of vemurafenib (VEM)-resistant lines. (a) A375R and SKmel-28R cells (closed squares) showed 410-fold increase in VEM GI50 (50%
growth inhibition) compared with their parent cell lines (open circles). SKmel-28R, but not A375R, are also crossresistant to MEK (mitogen-activated protein
kinase (MAPK)/extracellular signal–regulated kinase (ERK) kinase) inhibitor U0126 (5 μM). (b) Kinase signaling responses to DMSO control (labeled D), U0126 (U;
5 μM), and VEM (V; 5 μM) in A375, A375R, SKmel-28, and SKmel-28R lines. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)
analyses for differentially expressed genes between (c) the A375 and A375R pair and between (d) the SKmel-28 and SKmel-28R pair (e). A375R cells harbor a
BRAFΔ2-8 splice variant that is not present in either the native A375 cells or the SKmel-28/SKmel-28R pair. (f) Phosphotyrosine (pY)-receptor tyrosine kinase (RTK)
blot analysis shows increased pY-EGFR in the SKmel-28R cells as compared with the SKmel-28 cells, whereas (g) quantitative PCR (qPCR) analysis reveals
upregulation of HB-EGF and EGFR, but not EGF, in the SKmel-28R line.
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extracellular signal–regulated kinase (ERK) kinase) inhibition,
whereas SKmel-28R developed cross-resistance (Figure 1a
and b). We subsequently subjected all four sets of cell lines in
triplicate to comparative gene expression analysis.
Proﬁling of the A375 versus A375R pair revealed strikingly
sparse gene expression changes associated with the gain of
VEM resistance (Supplementary Figure S1 online). Of the
12,466 species surveyed, only 0.37% and 0.52% showed
42-fold induction and suppression, respectively, with
maximum changes ranging from a 5.8-fold induction of
MAGEA1 to a 6.7-fold suppression of SERPINA3 (Supple-
mentary Table S1 online). Gene Ontology (GO) and KEGG
(Kyoto Encyclopedia of Genes and Genomes) categories
affected by these minor expression variations (Figure 1c)
included “proliferation” (GO) and “inﬂammation” and “ECM”
(KEGG). As the A375R cells retained sensitivity to MEK
inhibitors (Figure 1a and b), we hypothesized that the
resistance lesion was upstream of MEK. Exome sequencing
(Supplementary Table S2 online) did not detect any acquired
mutations in NRAS, HRAS, KRAS, MAP2K1, MAP2K2, CRAF,
or BRAF, although there was a BRAF(Δ2-8) splice variant that
was present in the A375R but not the A375 parent line
(Figure 1e). This speciﬁc alteration has been reported in a
VEM-resistant human tumor specimen (patient no. 5 from a
recent report (Poulikakos et al., 2011)) and therefore is likely
driving VEM resistance in A375R cells.
In contrast to the A375 pair, expression analysis of SKmel-
28 versus SKmel-28R revealed signiﬁcant programmatic
changes with the emergence of VEM resistance
(Supplementary Figure S1 online). Overall, 3.4% and 3.0%
of the genes exhibited a 42-fold increase or decrease,
respectively, with a dynamic range of 114-fold induction
(IL1B) and 57-fold suppression (LOC728715, Supplementary
Table S1 online). GO analysis indicated major shifts in
“development/cell migration” genes whereas KEGG categor-
ization yielded numerous enrichments including “cancer“,
”cytokine”, and “metabolic processes” (Figure 1d). The
SKmel-28R cells lacked putative BRAF splice variants
(Figure 1e) and differed from the A375R cells in demonstrating
coresistance to both VEM and MEK inhibition (Figure 1a and
b). Comparative phosphotyrosine RTK blot analysis of the
SKmel-28 and SKmel-28R pair uncovered sustained EGFR
signaling on SKmel-28R cells (Figure 1f) that has been
reported to cause VEM resistance (Corcoran et al., 2012;
Girotti et al., 2013). There is no dramatic alteration of
phospho-EGFR in A375R (Supplementary Figure S1C). Addi-
tional exome sequencing of SKmel-28 and SKmel-28R did not
reveal biologically plausible acquired variants in EGFR,
NRAS, HRAS, KRAS, MAP2K1, MAP2K2, CRAF, or BRAF
(Supplementary Table S2 online). Taken together, these results
suggest that direct target modiﬁcation, such as the BRAF
splice product in A375R cells, neutralizes drug effects by
resetting a speciﬁc signaling pathway but leaves few
programmatic footprints. In contrast, EGFR activation in
SKmel-28R cells appears to be associated with more profound
gene expression alterations. We thus set out to clarify the
mechanism by which EGFR may have become activated in
the SKmel-28R cells.
As growth factors and cytokines are well-known activators
of RTK signaling, we ﬁrst interrogated these genes in the
microarray and found that a surprising number was upregu-
lated during the gain of resistance in SKmel-28. Among
candidate ligand–RTK pairings, HB-EGF-EGFR and GAS6-AXL
levels were all increased (Supplementary Figure S2 online),
although only EGFR appeared to be activated in the
phosphotyrosine RTK blot analysis (Figure 1f). Quantitative
PCR of SKmel-28R cells conﬁrmed a 39-fold increase in EGFR
and a 3.5-fold induction of heparin-binding EGF (HB-EGF)
compared with VEM-sensitive SKmel-28 cells (Figure 1g).
Thus, an EGFR autostimulatory circuit appears to be
selectively sustained and mediating resistance in the SKmel-
28R cells.
To experimentally validate the EGFR ﬁndings, we gener-
ated stable SKmel-28 lines expressing wild-type EGFR,
oncogenic EGFR(L858R), or kinase-dead EGFR(D837A)
(Figure 2a). In the absence of EGFR ligand, there was only a
minimal gain in VEM resistance in EGFR overexpression lines,
with the gains in VEM GI50s for SKmel-28
EGFR(WT), SKmel-
28EGFR(D837A), and SKmel-28EGFR(L858R) cells all o3-fold
compared with SKmel-28VECTOR (GI50= 0.75 μM). However,
on the addition of EGF or HB-EGF, VEM resistance was
dramatically enhanced in wild-type EGFR overexpression
lines (Figure 2a). There was a 36-fold and a 12-fold
increase in VEM GI50s when EGF or HB-EGF, respectively,
were exogenously added. As expected, the kinase-inactive
EGFR (D837A) allele had minimal effects on VEM
resistance even in the presence of EGF or HB-EGF. As both
AXL and GAS6 were also upregulated in SKmel-28R
compared with SKmel-28 cells in the microarray data, we
also transduced AXL into SKmel-28 cells. However, we
observed only minimal effects on VEM sensitivity either in
the absence or presence of exogenous GAS6 (Supplementary
Figure S3 online). These results indicate that overexpression of
EGFR alone may not be sufﬁcient to induce resistance and
that ligand upregulation is a critical component of an
“autocrine resistance loop”.
To elucidate determinants of this resistance loop, we
next performed transcriptional factor analysis on differen-
tially expressed genes in SKmel-28R versus SKmel-28
cells (Supplementary Table S3 online). As shown in
Figure 2b, MITF suppression was the leading transcriptional
footprint with a Z-score of −5.391 (P= 6.37× 10− 39); there
was also inhibition of SOX10 activity (Z-score, − 2.153,
P= 2.59×10−5). These ﬁndings are consonant with the
categorical change of “development/cell migration”
genes, as recovered by GO classiﬁcation of the micro-
array data. Validation of the microarray analysis by
quantitative PCR and western blotting conﬁrmed dramatic
reductions in MITF and MITF-M along with several
downstream MITF targets: BCL2, EDNRB, and miR-211
(Figure 2c). Overall, the acquisition of VEM resistance
in SKmel-28 cells appears to have silenced the entire
melanocytic program as positive upstream MITF regu-
lators (LEF1, PAX3, and SOX10) were all diminished whereas
the negative MITF regulator TCF4 was increased by 420-fold
(Figure 2c).
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To determine whether MITF loss cooperates with EGFR
activation in mediating resistance, we depleted MITF in the
stable EGFR SKmel-28 lines (Figure 2d) using small interfering
RNA (siRNA) and observed the acquisition of strong resistance
against both VEM (45-fold increase in GI50) and AZD6244
(300-fold increase in GI50) in the SKmel-28
EGFR(WT) cells
even in the absence of EGFR ligand (Figure 2d). The
siRNA-mediated depletion of MITF had no acute effects on
the amount of EGFR and EGF but did immediately increase
the levels of HB-EGF (3.6-fold) and transforming growth
factor-α (7.2-fold), both of which are known ligands for EGFR
(Figure 2e). In addition, neuregulin 1, an indirect activator of
EGFR through ERBB4 or ERBB3 binding, was also increased
5.1-fold after MITF knockdown (data not shown). These
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Figure 2. Loss of microphthalmia-associated transcription factor (MITF) contributes to an EGFR autocrine-resistance loop in SKmel-28R cells. (a) Stable
expression in SKmel-28 cells of EGFR (wild-type (WT)) or EGFR (L858R), but not kinase-dead EGFR (D837A), leads to vemurafenib (VEM) resistance in the
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ﬁndings indicate that MITF suppression may create an
autocrine ligand-rich environment that synergizes with EGFR
upregulation to mediate resistance.
In order to independently replicate the MITF/EGFR obser-
vation, we generated additional pairs of VEM-sensitive and
-resistant melanoma cell lines and found that the emergence
of VEM resistance in another line, MGH-CH1, was also
correlated with MITF loss and EGFR activation
(Supplementary Figure S4a and b online). Using the afore-
mentioned strategy, we stably introduced EGFR (WT), EGFR
(L858R), and EGFR (D837A) alleles into MGH-CH1 cells and
assessed VEM sensitivity. As shown in Supplementary Figure
S4c online, both MGH-CH1EGFR(WT) and MGH-CH1EGFR
(L858R) cells exhibited ligand-dependent VEM resistance
compared with MGH-CH1vector and MGH-CH1EGFR(D837A)
cells, consistent with the SKmel-28 results. Next, suppression
of MITF in MGH-CH1EGFR(L858R) cells also led to a gain of
resistance to both VEM and AZD6244 in the absence of
ligand (Supplementary Figure S4d online). In contrast to
SKmel-28 cells, however, the EGFR (L858R) allele seemed to
play a stronger role than wild-type EGFR in the MGH-
CH1 cells.
We next sought broader evidence of an interaction
between levels of MITF, EGFR, and therapeutic sensitivity.
First, we examined the CCLE (Cancer Cell Line Encyclopedia)
database (Barretina et al., 2012) and found signiﬁcant
correlations (Figure 3a) between PLX4720 resistance and
low MITF (P= 0.001), high EGFR (P= 0.0001), low LEF1
(P= 0.025), and high TCF4 (P= 0.011); PLX4720 insensitivity
was marginally related to low SOX10 (P=0.078) but not to
PAX3 (P= 0.76). In addition, copy number analysis using a set
of BRAF(V600E) melanoma lines (Ji et al., 2012) revealed that
MITF ampliﬁcation is associated with increased sensitivity to
both VEM and the MEK inhibitor U0126 (Supplementary
Figure S5 online), further strengthening the role of MITF in
melanoma’s response to mitogen-activated protein kinase
pathway inhibition. Thus, the pattern of lineage silencing,
high EGFR, and SBI insensitivity appears to be preserved
across a panel of melanoma lines. We next set out to conﬁrm
the relationship between acquired VEM resistance and MITF
levels in tumor specimens. We ﬁrst examined changes in
MITF expression using a publicly available microarray data
set (Gene Expression Omnibus (GEO) GSE50509) that
captured gene expression data for 20 pretreatment and 30
relapse melanoma specimens from 20 patients. As shown in
Figure 3b, the majority of relapsed tumors showed evidence
of MITF loss. As EGFR probes in GSE50509 did not pass our
quality ﬁlter, we also veriﬁed trends in MITF and EGFR
expression by quantitative PCR using an in-house collec-
tion of BRAF (V600E)-mutated tumors from patients treated
with BRAF+MEK inhibitors. The average relative log2-fold
change between pre- and post-relapse specimens was
−0.88 for MITF and 0.61 for EGFR (Figure 3c; P=0.002). In
4/5 tumor pairs, the relapse specimen had lower MITF levels
but higher EGFR levels compared with the pretreatment
samples.
The overall expression patterns that relate both MITF and
EGFR to VEM response also suggest that the two molecules
may exhibit innate reciprocity. First, a signiﬁcant negative
correlation between MITF and EGFR was identiﬁed in the 28
CCLE melanoma lines (Figure 4a; Po0.0001). Turning to
melanoma specimens rather than cell lines, signiﬁcant
reciprocal relationships were also observed in the 374 tumors
(Po0.0001) available through The Cancer Genome Atlas
(TCGA; Figure 4b and Supplementary Table S4 online) and 31
primary melanomas (P= 0.0005) and 71 metastatic mela-
noma specimens (P= 0.0007) available in the GEO
(GSE46517; Figure 4b and Supplementary Table S4). Implicit
in these ﬁndings is the possibility that MITF may directly
counterregulate EGFR signaling. To test this hypothesis, we
induced MITF expression for short term in A375 and MGH-
CH1 cells using the Tet-on system (Figure 4c). In the A375
cells, there was a modest reduction in EGFR but a complete
abrogation of pEGFR. In the MGH-CH1 cells, there was a
dramatic loss of EGFR, although basal levels of pEGFR were
undetectable. Interestingly, with the acute elevation of MITF
levels, there appeared to be a dose-dependent growth
retardation in both cell lines (Supplementary Figure S6).
In order to directly assess the drug-sensitizing effects of
MITF, we used a set of immortalized primary melanocyte lines
(Pmel; Figure 5a) that have stably incorporated BRAF(V600E)
alone (Pmel-BRAF*) or both BRAF(V600E) and MITF (Pmel-
BRAF*-MITF) together(Garraway et al., 2005). These cells
were selected because they harbor the minimal essential
elements for deﬁning drug response. As shown in Figure 4a,
the native Pmel line had low MITF expression and no BRAF
(V600E) as assessed by the VE-1 antibody. EGFR was clearly
expressed in both the Pmel and Pmel-BRAF* cells. On the
other hand, Pmel-BRAF*-MITF cells had near abolition of
EGFR expression. The Pmel-BRAF*-MITF cells were also
signiﬁcantly more sensitive to the selective BRAF inhibitor
PLX4720 and MEK inhibitor U0126 (Figure 5b) compared
with both Pmel and Pmel-BRAF* cells, suggesting that the
addition of MITF conferred enhanced drug sensitivity even in
cells with extant BRAF (V600E). We next determined whether
MITF can have a similar impact on drug response in
nonpigment cells by using a Tet-on MITF system that was
engineered into the BRAF (V600E)-mutated HT29 colon
cancer line. Forced expression of MITF reduced the levels
of pEGFR (Figure 5c) and engendered a410-fold increase in
sensitivity (as measured by GI50s) to both VEM and AZD6244
(Figure 5d). These results support a role for MITF in regulating
EGFR and in modulating drug response for both pigment cells
and nonpigment cells.
DISCUSSION
Acquired therapeutic resistance in melanoma has been
ascribed to various mechanisms. However, the relationship
between these acquired lesions and underlying transcriptional
programs is not well deﬁned. Our studies suggest that a
balance between lineage identity and RTK activation mod-
ulates drug sensitivity. More speciﬁcally, loss of MITF
potentiates an EGFR “autocrine resistance loop” that is not
normally utilized by the melanocyte lineage that then
mediates therapeutic resistance.
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Our analysis of the CCLE data (Barretina et al., 2012), and
those of others (Konieczkowski et al., 2014), supports the
notion that melanomas with weak lineage identity (low MITF,
LEF1, and SOX10) appear to be more resistant to PLX. This
hypothesis would harmonize with the rapid ability of
colorectal cancers to utilize a lineage-appropriate expression
of EGFR to undermine the effects of SBIs in tumors with BRAF
mutations (Corcoran et al., 2012; Prahallad et al., 2012). Thus,
cells with nominal MITF may predominate during the course
of selection. Alternatively, MITF may directly, or indirectly,
suppress the EGFR signaling system (Figure 5e) as suggested
by our experiments modulating MITF in immortalized
melanocytes, melanoma, and colon cancer cells. The use of
Pmel cells with stable and genetically deﬁned elements (i.e.,
BRAF (V600E) and MITF) provides perhaps the most precise
and direct evidence that MITF-enriched cells adopt a low-
EGFR state that is more drug sensitive. With forced MITF
expression in A375 and MGH-CH1 melanomas and HT29
colon cancer cells, there was a direct reduction of EGFR and/
or pEGFR.
We also observed an increase in pEGFR with siRNA-
mediated MITF depletion but only when cells were stably
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Results are shown as log2 ratios normalized to the mean intensity of pretreatment samples. (c) Relative (postrelapse to pretreatment) and normalized (to GUSB)
levels of MITF and EGFR in clinical specimens from patients on BRAF/MEK inhibitor trials. RNA levels were determined by quantitative PCR (qPCR). There is a
signiﬁcant trend toward decreased MITF expression and increased EGFR expression in the postrelapse samples compared with pretreatment samples. Dab,
dabrafenib; RECIST, response evaluation criteria in solid tumors; Tx, treatment; Tram, trametinib.
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endowed with ectopic EGFR. Both SKmel-28 and MGH-CH1
lines express robust levels of MITF but exquisitely low levels
of EGFR. The prevalence of this phenotype across the
melanoma population may explain the markedly higher
response rate to SBIs compared with BRAF mutant colorectal
cancer. The cooperativity between MITF depletion and
overexpression of EGFR and its ligands suggests that MITF
loss may contribute to resistance by augmenting levels of
ligands, such as HB-EGF and transforming growth factor-α,
neuregulin 1, or IL-8, that has reported to be negatively
regulated by MITF (Hari Kishore et al., 2012) and that is
known to transactivate EGFR (Itoh et al., 2005). Interestingly,
a recent report shows that IL-8 signaling can induce
chemoresistance by maintaining melanoma-initiating cells
(Wilson et al., 2014). Finally, low MITF and high EGFR (and
perhaps AXL (Konieczkowski et al., 2014)) could mark
exclusive cellular states that harbor distinct therapeutic
susceptibilities unrelated to the direct function of these
proteins. This static view is supported by the innate
reciprocity between MITF and EGFR expression that is
preserved across multiple collections of melanoma tumors
for which expression data are available (Figure 4a and b).
However, the precise mechanism(s) by which MITF interacts
with the EGFR signaling system remains the subject of
ongoing investigation.
Although there is burgeoning appreciation for a link
between melanocyte lineage identity and RTK signaling,
there have been several reports examining the role of MITF in
dictating drug response. On one hand, Smith et al. (2013)
found that when A375 cells were induced into resistance
against MEK inhibition, emergent subclones exhibited higher
MITF and SMURF2 levels. Along these lines, Johannessen
et al. (2013) used A375 cells in a reverse screen and found
that genes in the cAMP pathway induced MITF, strengthened
lineage identity, and conferred resistance to RAF, MEK, and
ERK inhibitors ; it is worth noting, however, that one of the
patient tumors reported in the paper clearly showed loss of
MITF with relapse (no. 16; extended data Figure 10d in
reference Johannessen et al., 2013). On the other hand,
Konieczkowski et al. (2014) found that intrinsic PLX resistance
is associated with low MITF along with high NF-κB levels. In a
related study, Sun et al. (2014) also showed that depletion
of lineage factor SOX10, but not MITF, increased EGFR and
VEM resistance. In that report, sh(MITF) did not alter VEM
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Figure 4. Reciprocity between microphthalmia-associated transcription factor (MITF) and EGFR in melanoma. (a) An inverse relationship between levels of
MITF and EGFR can be observed across 28 CCLE (Cancer Cell Line Encyclopedia) melanoma samples and (b) 374 melanoma tumor specimens in the TCGA (The
Cancer Genome Atlas) and 31 primary melanoma tumors and 71 metastatic (Met) melanoma specimens from GSE46517. Linear regression indicated within dot
plot; of note, the TCGA data are plotted in log–log scale and thus the linear regression line appears downwardly curved. (c) Induction of MITF in A375 and MGH-
CH1 cells using a Tet-on promoter leads to a complete suppression of pEGFR and a slight decrease in EGFR in the A375 cells and a signiﬁcant decrease in EGFR
in the MGH-CH1 cells. Dox, doxycycline.
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sensitivity although it may be related to the cell line used; in
our hands, SKmel-28 cells have 11-fold more MITF than A375
cells (data not shown) and thus the A375 cells may have
come to depend on SOX10 signaling to a greater extent.
Instead of inducing resistance by SOX10 loss only, our study
indicates that MITF loss only confers resistance in the
presence of EGFR expression.
Our data indicate that RTK-induced resistance is dependent
on ligand, and this broadens the picture of growth factors in
drug resistance that was initially suggested in paracrine
hepatocyte growth factor–induced primary BRAFi resistance
(Straussman et al., 2012; Wilson et al., 2012). Our data are
also consonant with a recent report that high EGFR-expressing
cells often lack EGFR activation, presumably because of lack
of ligands, and are still sensitive to BRAFi; thus, EGFR levels
alone cannot be used as a biomarker of vemurafenib
resistance (Gross et al., 2014). Our results also suggest that
ligand measurement in blood or other body ﬂuid might be an
eventual method to predict drug resistance clinically. It is
intriguing that stable EGFR phosphorylation by constitutively
active L858R mutant does not induce resistance, an insight
from which might offer a more detailed understanding of
EGFR-dependent resistance and strategies to overcome
resistance.
In summary, lineage reprogramming appears to be directly
coupled to RTK activation in the setting of therapeutic
resistance. These comparative molecular studies provide a
framework for understanding shifts in transcriptional states as
resistance lesions emerge under drug selection. Efforts are
now underway to recover useful therapeutic agendas to
overcome these programs.
MATERIALS AND METHODS
Compounds, antibodies, and reagents
Vemurafenib, PLX4720, AZD6244, and U0126 were from Selleck
Chemicals (Houston, TX). EGF, HB-EGF, and p-RTK arrays were
purchased from R&D (Minneapolis, MN). Doxycycline was from
Clontech (Mountain View, CA). Antibodies against p-EGFR, EGFR,
BRAF, p-MEK. MEK, p-ERK, ERK, p-AKT, AKT, GAPDH, and α-
tubulin were from Cell Signaling (Danvers, MA). CellTiter-Glo cell
viability assay was from Promega (Madison, WI). AlamarBlue cell
viability reagent was from Life Technologies (Grand Island, NY).
Human phospho-RTK array kit was from R&D Systems. The siRNA
against MITF and nontargeting control siRNA were from GE
Dharmacon (Lafayette, CO).
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Figure 5. Overexpression of microphthalmia-associated transcription factor (MITF) confers therapeutic sensitivity. (a) Immortalized primary melanocytes
(Pmel) with stable expression of BRAF (V600E) and MITF (Pmel-BRAF*-MITF) have lower EGFR levels than either control Pmel cells or Pmel cells with only BRAF
(V600E) (Pmel-BRAF*). (b) Pmel-BRAF*-MITF (solid triangle) cells are more sensitive to both PLX and U0126 than Pmel (open circle) and Pmel-BRAF* (solid
squares) cells. (c) The colon cancer cell line HT29, which harbors a BRAF(V600E) mutation, was transduced with a Tet-on vector (TetGFP) or Tet-on MITF
(TetGFP-MITF) and induced to express MITF using the indicated doses of doxycycline (Dox). (d) Induced expression of MITF in HT29 leads to increased sensitivity
to vemurafenib and AZD6244, as determined by a410-fold reduction in the GI50 (50% growth inhibition). (e) One possible model suggests that MITF, or other
lineage determinants, may inﬂuence therapeutic resistance by modulating levels of ligand (e.g., heparin-binding EGF (HB-EGF)), receptor tyrosine kinases (RTKs;
such as EGFR) or other downstream components of RTK signaling.
Z Ji et al.
MITF and Resistance
1870 Journal of Investigative Dermatology (2015), Volume 135
Long-term cell proliferation assays
Cells were seeded into 6-well plates (1× 104 cells per well) and
cultured both in the absence and presence of drugs as indicated.
After 10–15 days, cells were ﬁxed with paraldehyde and stained with
1% crystal violet for 10minutes. The plates were then washed with
ddH2O and dried in air before photographed.
Drug treatment and cell viability assay
Cell viability was determined by AlamarBlue (Life Technologies)
ﬂuorescence assay and CellTiter-Glo (Promega) luminescence
assay. Approximately 12 hours before drug treatment, cells were
seeded at a density of 3,000 cells (100 μl) per well in a 96-well
plate. The plates were incubated with drugs for 48 hours. To each
well, 10 μl of AlamarBlue was added and incubated for 3 hours at
37 °C. AlamarBlue is ﬂuorescent substrates reduced by mito-
chondrial enzyme activity in viable cells. Alternatively, 30 μl of
CellTiter-Glo was added to each well and incubated, protected from
light on an orbital shaker, for 10 minutes. CellTiter-Glo contains
luciferase that catalyzes the oxygenation of luciferin (creating light)
according to the amount of adenosine triphosphate present.
Fluorescence or luminescence intensity was determined using a
Molecular Devices (Sunnyvale, CA) plate reader with an excitation
ﬁlter centered on 540 nm and an emission ﬁlter centered on 590 nm
or with an integration time of 500ms and measuring total light
emitted, respectively. GI50s were calculated using the software
CompuSyn (http://www.combosyn.com).
Stable infections
Lentiviral transduction was used to alter the levels of MITF. Lentiviral
supernatant was produced by transient transfection of HEK293T cells
(ATCC, Manassas, VA) using lipofectamine (Life Technologies),
according to the manufacturer’s instructions. The viral-containing
supernatants were harvested 48 hours after transfection and ﬁltered
through a 0.45 μm ﬁlter unit. To transduce melanoma cells with
lentivirus, logarithmically growing melanoma cells were seeded at a
density of 2× 105 cells per well in 6-well plates. A total of 0.5 ml of
lentivirus suspension and 8 μgml−1 of polybrene were added to
DMEM with 10% fetal bovine serum in a total volume of 1 ml. Cells
were incubated at 37 °C for 12 hours before removing the medium
and replacing with 2 ml of fresh DMEM for expansion of the
transductants. Cells were selected with puromycin at 1.5 μmol l− 1 for
another 5 days before further experiments.
Protein lysate preparation and immunoblots
Cells were seeded in medium containing 10% fetal bovine serum
for 24 hours, and then washed with phosphate-buffered saline
and lysed with RIPA buffer supplemented with Halt protease
inhibitor cocktail (Thermo Scientiﬁc, Rockford, IL). Equal amounts
of protein (5–20 μg) were loaded onto 4–20% SDS polyacrylamide
mini-gels (Bio-Rad, Hercules, CA) and transferred to polyvinylidene
diﬂuoride membranes. After being blocked in 5% milk in Tris-
buffered saline–Tween for 1 hour, blots were incubated with primary
antibodies overnight, followed by horseradish peroxidase–
conjugated secondary antibody (1:5,000) for 45minutes. Antigen–
antibody complexes were detected by enhanced chemilumines-
cence. Human p-RTK arrays were performed according to the
manufacturer’s instructions.
Melanoma patient tumor samples
Human melanoma specimens (all BRAF V600 mutated) were
obtained from patients undergoing treatment with vemurafenib,
dabrafenib, or trametinib in accordance with a protocol approved by
the MGH institutional review board. All patients provided written
informed consent for analysis, as approved by the Dana-Farber/
Harvard Cancer Center Institutional Review Board (DF/HCC Protocol
11-181).
RNA isolation and reverse transcriptase–PCR
RNA isolation from cell lines harvested with TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. Complemen-
tary DNA (cDNA) synthesis was performed with Maxima Universal
First-Strand cDNA Synthesis Kit (K1661, Thermo Scientiﬁc, Rockford,
IL) according to the manufacturer’s instructions. The cDNA was
obtained by reverse transcription using High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Waltham, MA) according to
the manufacturer’s instructions. Levels of individual genes were
quantiﬁed using a TaqMan Gene Expression Assays (Life Technologies)
as previously described (Yang et al., 2006): EGFR (Hs01076078_m1),
EGF (Hs01099999_m1), HB-EGF (Hs00181813_m1), MITF (Hs01117294_
m1), TCF4 (Hs00162613_m1), MIR211 (Hs04231471_s1), TGFA
(Hs00608187_m1), SOX10 (Hs00366918_m1), BCL2 (Hs00608023_m1),
PAX3 (Hs00240950_m1), LEF1 (Hs01548150_m1), CREB1
(Hs00231713_m1), and NRG1 (Hs00247620_m1). Human GUSB
(4333767 T, Life Technologies, Grand Island, NY) was used as an
endogenous control. Primer sequences for MITF-M were from Dynek
et al. (2008). Real-time PCR was performed using the LightCycler480
(Roche, Indianapolis, IN) at 95 °C for 10minutes for denaturation and
then 95 °C for 10 seconds and 60 °C to 62 °C for 50 seconds for 45
cycles. The normalized, relative levels of the genes between samples
were expressed as the log2 ratio (e.g., − 10= 2−10= 1,024-fold
reduction in expression in sample 1 vs. sample 2).
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